Key facts
- iCHOR’s last known valuation is $12.0M (Jan 2024).
- It has raised $6.1M; the latest was Angel (individual) in Apr 2025.
- Notable investors include Band of Angels, Alliance of Angels, Ariel Savannah Angel Partners, Central Texas Angel Network, IrishAngels — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for iCHOR
- ·The full record, as it builds
Funding rounds
No funding rounds for iCHOR are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About iCHOR
Developer of a medical device designed to treat peripheral vascular occlusions. The company's percutaneous system replicates the parameters of surgical thrombectomy or embolectomy to perform simplified and safe clot removal without capital equipment or lytics, enabling doctors to potentially reduce risks like scarring, valve damage, and blood loss.
- Sector
- Healthcare
- HQ
- Boca Raton, FL, United States
- Founded
- 2014
- Employees
- 8
- Website
- ichorvascular.com/
- Ownership
- Privately Held (backing)
iCHOR doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in iCHOR shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on iCHOR in its N-PORT filings yet. We sweep new filings monthly.